Articles tagged with Lupus
Researchers developed a math model that can predict the progression from nephritis to interstitial fibrosis in lupus patients. The model can also gauge the effectiveness of experimental treatments for inflammation and fibrosis, reducing the need for invasive biopsies.
Yale Cancer Center researchers have found that lupus antibodies can selectively attack and kill cancer cells with defective DNA repair mechanisms. The study, led by James E. Hansen, suggests that harnessing these antibodies could be a new approach to targeted cancer therapy.
Researchers have identified a specific genetic mutation causing lupus in a young patient through DNA sequencing. The discovery opens the door to personalized treatments targeting individual patients' unique genetic causes.
Lupus and other rheumatologic diseases can initially present as neurological disorders such as headaches and seizures, leading to delayed diagnoses. Treatments for these conditions can also cause adverse neurological effects.
A new study found that black and Hispanic SLE patients were more likely to be readmitted to the hospital within 30 days of discharge compared to white patients. Lupus patients with kidney inflammation, serositis, or low blood platelet count were also at higher risk for early readmissions.
A biomedical engineer has received a $250,000 grant to expand his research on a novel lupus drug that targets B cells. The goal is to treat a range of autoimmune diseases, offering an alternative to steroids with fewer side effects.
Researchers found that lower doses of glucocorticoids and pulsed therapy can be as effective as traditional treatments, with fewer side effects. The study suggests using anti-malarial drugs, such as hydroxychloroquine, as a long-term treatment option.
Researchers found that anti-dsDNA, surface-expressed TLR4, and endosomal TLR9 cooperate to worsen lupus progression. Co-activation of these receptors triggers a more intense immune response, leading to increased disease severity.
Lupus patients can successfully stop immunosuppressant therapy without triggering a flare by slowing down the tapering process and checking for positive serology. The study found that within two years, about 70% of clinically stable patients were able to stop their medication.
A biomedical engineer at UH is studying a potential treatment for lupus nephritis by targeting the interaction between three specific molecules. The goal is to determine if blocking this pathway can prevent kidney inflammation and failure.
A person with both lupus and HIV was found to produce the correct type of neutralizing antibodies, a key component of an effective vaccine. The study provides new insights into the immune system's response to the virus and could aid in the development of vaccines capable of overcoming tolerance controls.
Researchers at Yale University found that a combination of hydroxychloroquine may partially reverse the detrimental effects of antiphospholipid antibodies on human placental cell function, potentially benefiting pregnant women with lupus and/or antiphospholipid syndrome. This could lead to improved pregnancy outcomes for these patients.
Researchers at Northwestern University have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease. The study found that the peptides can block and reduce autoantibody production to almost baseline levels, showing potential as a vaccine-like therapy.
A new study published in Arthritis & Rheumatism found that headaches in lupus patients are not linked to disease activity or specific autoantibodies. The study of over 1,700 lupus patients showed that nearly all headache episodes resolved on their own without treatment.
A study at Hospital for Special Surgery identified an imbalance of angiogenic factors as a predictor of poor pregnancy outcomes in lupus patients. Elevated levels of anti-angiogenic protein sFlt1 and lower levels of placental growth factor (PIGF) were associated with increased risk of preeclampsia and other complications.
A new study found that young black women in Southeastern Michigan have the highest rate of developing lupus and are more likely to experience serious health complications. Lupus prevalence was three times higher among black females compared to white women, with a higher risk of kidney and neurologic complications.
Associate Professor David Tarlinton will receive $1 million funding to study immune cells causing lupus. He aims to develop treatments that prevent or reverse the disease by inhibiting harmful antibody production.
Researchers at Bonn University have discovered that UV-light induced DNA damage triggers lupus-like autoimmune symptoms by activating the cGAS signaling pathway. This study provides a crucial understanding of the immune mechanism behind lupus and offers potential new therapy targets.
Researchers identified gene variants associated with an increased risk of kidney problems in lupus patients, which could lead to better treatments to protect kidney health. The study found that variants in the ABIN1 gene were linked to an increased risk of lupus nephritis, a common complication of the disease.
George Tsokos, MD, has received a prestigious MERIT Award from the National Institutes of Health (NIH) for his longstanding work investigating molecular T-cell defects underlying systemic lupus erythematosus (SLE). The funding will support his project and provide insights into disease diagnosis and therapeutic targets.
Researchers developed a nanogel-based delivery system targeting immunosuppressive drug mycophenolic acid at tissues associated with immune cells. The treatment showed improved survival rates and delayed kidney damage in mouse models of lupus.
Scientists identified nitric oxide's role in degrading a protein that attenuates cardiac growth, linking vascular changes to heart size. A nanogel-based treatment targeting an immunosuppressive drug directly to tissues associated with immune cells may help treat systemic lupus erythematosus.
Researchers have identified plasmacytoid dendritic cells (pDCs) as a key producer of type I interferons in lupus, which can be targeted to prevent autoimmunity. Blocking this pathway may offer a potent weapon against the disease.
A landmark study published in Annals of the Rheumatic Diseases found that lupus patients taking immunosuppressive medications do not have a significantly increased risk of developing lymphoma. The study involved nearly 5,000 cancer-free lupus patients and found no clear association between disease activity and lymphoma risk.
A new study conducted by scientists at the University of Cincinnati and Cincinnati Children's Hospital Medical Center found a strong correlation between uranium exposure and an increased lupus rate. People who were exposed to higher levels of uranium had lupus rates four times higher than the average population.
Studies found that lupus patients who underwent knee replacement surgery experienced few adverse events, with outcomes similar to those of osteoarthritis patients. Rheumatoid arthritis (RA) patients also performed similarly after joint replacement surgery, with no significant differences in operation time or post-surgical complications.
The Lupus Research Institute has awarded $1 million to University of Massachusetts Medical School faculty for research on toll-like receptors in lupus. The award will explore the role of TLR proteins in the disease and identify new targets for therapies.
A Mayo Clinic study reveals that mice exposed to low doses of a staph protein developed a lupus-like disease, with kidney damage and autoantibodies. The findings suggest that the protein may play a role in exacerbating lupus in genetically predisposed patients.
A study by Hospital for Special Surgery researchers has demonstrated that women with a specific type of antibody are at risk for adverse pregnancy outcomes. The study found that antiphospholipid antibodies (aPLs), particularly lupus anticoagulant, increase the risk of complications such as fetal death, preterm delivery, and preeclampsia.
The American College of Rheumatology has released new guidelines for the screening, treatment, and management of lupus nephritis. The guidelines include methods for identifying renal disease, newer therapies, and treatment of pregnant patients with kidney involvement. Patient survival rates are significantly lower when lupus nephritis ...
Researchers found that infection with gammaherpesvirus 68 significantly reduces lupus symptoms in mice, including decreased antibodies, reduced tissue damage, and inhibited activation of lymphocytes and dendritic cells. The study suggests a possible mechanism for how the virus protects against autoimmunity.
Researchers identify IRF8 and TMEM39a as associated with lupus in European-American, African-American, Gullah, and Asian patients. The study's findings also suggest that the genes may not be universal, highlighting the need for further research.
Researchers found an enzyme called IDO helps clear cellular debris and promote tolerance to the body's own proteins and DNA. Blocking IDO can trigger autoimmune diseases like lupus in genetically programmed mice.
Biologist Harmit Malik aims to understand whether a lost evolutionary arms race causes lupus autoimmunity. He investigates the role of parasitic 'jumping genes' and their interaction with defense mechanisms, which may provide a new model for understanding lupus.
Italian researchers found a DNA sequence called enhancer HS1.2 that accelerates the activity of genes involved in Lupus, an autoimmune disease affecting 60,000 people in Italy. The discovery could lead to more effective therapies against severe cases of Lupus.
A new study finds mycophenolate mofetil superior to azathioprine as a maintenance therapy for lupus nephritis, with improved patient outcomes and reduced side effects. The study included 227 patients from 19 countries and showed that mycophenolate mofetil was more effective in treating the condition.
A new study found that more than 80% of lupus patients with end-stage renal disease opt for hemodialysis, while those without insurance or employed are less likely to choose peritoneal dialysis. The study highlights the impact of socioeconomic factors on kidney replacement therapy choices among lupus patients.
Women with lupus can safely carry out pregnancy thanks to recent advances in rheumatology research, according to a study led by Jane Salmon. The study found that 80% of patients had a favorable pregnancy outcome when they had inactive lupus at the time of conception.
A multicenter NIH-funded study found that most women with stable lupus can have successful pregnancies, with 80% of patients experiencing favorable outcomes. The study's findings highlight the importance of timing and avoiding pregnancy during periods of increased disease activity.
A study found that lupus patients with low socioeconomic status often miss appointments due to transportation and childcare issues. The researchers suggest improving transportation services or temporary childcare as a potential approach to ensure these patients receive necessary care.
Experts from NYU Langone Medical Center presented new research findings on osteoarthritis, lupus, and rheumatoid arthritis at the American College of Rheumatology 2011 Annual Scientific Meeting. A study found that increased prescription of narcotic analgesics for OA in the elderly is associated with increased falls and fractures.
A study published in Arthritis & Rheumatism found that statin therapy did not slow the progression of atherosclerosis in children and adolescents with systemic lupus erythematosus (SLE). However, patients with more severe SLE may benefit from preventative statin therapy. The study also showed that atorvastatin was safe and well-tolerated.
The current classification system for lupus nephritis is too detailed and may make it harder for clinicians to treat kidney problems in patients with lupus. A new study analyzing data from 86 patients found no significant difference in health outcomes between segmental and global forms of class IV lupus nephritis.
A study by researchers at Albert Einstein College of Medicine found that close supervision by rheumatologists and the use of immunosuppressant drugs can improve the survival of lupus patients with end-stage kidney disease. Patients who visited their rheumatologist regularly had significantly higher four-year survival rates compared to ...
A Cleveland Clinic researcher has received a $1.1 million grant to investigate why females are disproportionately affected by lupus. The study will explore the role of immunosuppressive cells in the development of the disease and its impact on males.
Researchers at Boston University have found four new genetic variants associated with a higher risk of systemic lupus erythematosus (lupus) in African American women. The study, based on data from the Black Women's Health Study, reveals that these genetic factors may be shared among women of different genetic ancestries.
A Chinese study shows that HPV vaccine Gardasil does not increase disease flares or antibody measures in inactive SLE patients receiving stable medications. The study confirms the safety of Gardasil vaccination to prevent HPV infection in this population.
Research shows that African Americans with systemic lupus erythematosus (SLE) have a higher antibody response to the influenza vaccine compared to European American patients. Treatment with prednisone and history of hemolytic anemia are linked to low antibody responses in SLE patients.
Researchers found that umbilical cord blood-derived mensenchymal stem cells (uMSCs) can delay renal function deterioration and alleviate symptoms of lupus nephritis. Early transplantation with allogenic MSCs showed the most promising results, supporting their potential use in treating systemic lupus erythematosus.
The S.L.E. Lupus Foundation has awarded grants to three New York City-based researchers to explore potential treatments and causes of lupus. The foundation's investment has surpassed $17 million, making it a leader in lupus research and care.
Research reveals significant increases in ESRD incidence among patients with lupus nephritis, particularly in younger populations and African Americans. Despite advances in treatment, outcomes have not improved over a decade, highlighting the need for further research to identify modifiable risk factors and interventions.
Researchers identified genetic errors in women with autoimmune diseases and preeclampsia, suggesting new treatments and screening tests. The study found mutations in three genes involved in the immune response to injury, providing a potential link between preeclampsia and atypical hemolytic uremic syndrome.
Researchers identified genetic mutations in women with lupus and/or antiphospholipid antibodies that may predispose them to preeclampsia. The study's findings suggest new targets for treating the condition and raising the possibility of tests to identify women at increased risk
The Lupus Research Institute has awarded $3.6 million in grants to support cutting-edge research on the devastating disease. Investigators will explore how the immune system goes awry and develop novel approaches to correct manifestations that cause tissue and organ damage.
A study by Dana-Farber Cancer Institute researchers has identified a regulatory defect that drives lupus. Correcting this defect may represent an effective therapeutic approach to systemic lupus erythematosus-like autoimmune disease.
A study published in PLOS ONE reveals a common set of dysregulated miRNAs in murine lupus models, which may lead to the development of molecular markers for early diagnosis and therapeutic interventions. The findings could ultimately improve the treatment and management of autoimmune diseases like lupus.
Researchers found that IFN-a priming promotes lipid uptake and foam cell formation in lupus patients, increasing the risk of premature plaque build-up. This activation of the IFN signaling pathway may be linked to the increased cardiovascular risk in SLE patients.
A new study finds that dendritic cells play a key role in amplifying autoimmune disease, specifically systemic lupus erythematosus (SLE). The research suggests that depleting dendritic cells may be a potential therapeutic strategy for treating SLE and potentially other autoimmune diseases.
The Mary Kirkland Center offers personalized care to lupus patients through a team of healthcare professionals. The center provides education and research opportunities, as well as programs addressing cardiovascular health and wellness, to improve patient outcomes.
A new assessment tool, SMILEY, helps shed light on the quality of life of children with lupus around the world. The study found that parents and children perceive the disease differently, with Asian countries reporting a better quality of life than Europe or South America.